Company Monitoring Page for MannKind

latest headlines for company on cafepharma

MannKind announces FDA acknowledgement of NDA resubmission for Afrezza
Yahoo/Fly on the Wall
Wed, 10/30/13 - 09:45 am
Tags:
diabetes, inhaled insulin, MannKind, FDA, Afrezza
Could This New Drug Application Lead to a Giant Leap for MannKind?
Motley Fool
Thu, 10/17/13 - 06:14 pm
Tags:
MannKind, Afrezza, diabetes, Pfizer
MannKind asks for approval of Afrezza 2 years after FDA asked for more studies; shares rise
Yahoo/AP
Mon, 10/14/13 - 09:32 am
Tags:
inhaled insulin, MannKind, diabetes, Afrezza, FDA
3 Companies at the Cutting Edge of Diabetes Research
Motley Fool
Fri, 09/27/13 - 08:18 am
Tags:
diabetes, Eli Lilly, Merck, MannKind
What's MannKind Really Worth?
Motley Fool
Wed, 09/18/13 - 08:51 am
Tags:
MannKind, Afrezza, diabetes
Will History Repeat for Inhaled Insulin?
Motley Fool
Thu, 09/12/13 - 08:03 am
Tags:
inhaled insulin, Afrezza, MannKind, diabetes
Novo Nordisk Pushes Ahead In Challenging Year
Investors.com
Tue, 09/10/13 - 04:48 pm
Tags:
Novo Nordisk, Sanofi, Bristol-Myers Squibb, diabetes, Eli Lilly, MannKind
Is This a MannKind Killer?
Motley Fool
Tue, 09/3/13 - 09:54 am
Tags:
MannKind, diabetes, Afrezza, BIOD-123, insulin, Biodel
MannKind Talks Down Insider Selling While Executives Sell Shares
TheStreet.com
Thu, 08/29/13 - 09:47 am
Tags:
MannKind
Challenges In Commercializing Inhaled Insulin
Forbes
Thu, 08/22/13 - 09:08 am
Tags:
inhaled insulin, Afrezza, MannKind
3 New Diabetes Drugs Possibly on the Way Soon
Motley Fool
Wed, 08/21/13 - 09:03 am
Tags:
diabetes, Forixga, AstraZeneca, Bristol-Myers Squibb, dulaglutide, Eli Lilly, Afrezza, MannKind
MannKind's Steady Progression Towards FDA Approval Continues Unabated
Seeking Alpha
Mon, 08/19/13 - 09:43 am
Tags:
MannKind, FDA, Afrezza, diabetes, insulin, inhaled insulin, Eli Lilly, Pfizer, Novo Nordisk
This Week in Biotech
Motley Fool
Sun, 08/18/13 - 11:58 am
Tags:
Osiris Therapeutics, Inovio, GSK, Gilead Sciences, Forrest, Almirall, Theravance, MannKind
A Closer Look at 3 Players in Diabetes Treatments
Motley Fool
Sat, 08/17/13 - 10:54 am
Tags:
type 2 diabetes, type 1 diabetes, Osiris Therapeutics, MannKind, diabetes, NovoNordisk
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sat, 08/17/13 - 10:47 am
Tags:
Merrimack Pharmaceuticals, MannKind, Synta Pharmaceuticals
Positive Data on MannKind's Afrezza
Yahoo/Zacks
Sat, 08/17/13 - 10:38 am
Tags:
MannKind, diabetes, Afrezza, type 2 diabetes
MannKind rewarded for positive Afrezza data with $40M financing
Fierce Biotech
Fri, 08/16/13 - 10:47 am
Tags:
MannKind, Afrezza, diabetes, inhaled insulin
Our BioPharma Catalyst Watch List
Seeking Alpha
Thu, 08/15/13 - 12:09 pm
Tags:
Astex, Biodel, Insmed, MannKind, Onconova, Afrezza, Dacogen, Arikace, Rigosertib
Drug developer MannKind posts larger 2Q loss
Yahoo/AP
Sat, 08/10/13 - 12:22 pm
Tags:
MannKind, earnings
Oramed Expands Diabetes Platform With Oral GLP-1 Agonist
Seeking Alpha
Tue, 08/6/13 - 10:00 am
Tags:
GLP-1 agonist, diabetes, Oramed, Biodel, Bristol-Myers Squibb, Eli Lilly, MannKind, Novo Nordisk, Merck, Afrezza, Januvia, Victoza

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.